These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37771727)

  • 1. A physiologically based pharmacokinetic model for V937 oncolytic virus in mice.
    Peribañez-Dominguez S; Parra-Guillen ZP; Freshwater T; Troconiz IF
    Front Pharmacol; 2023; 14():1211452. PubMed ID: 37771727
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling.
    Parra-Guillen ZP; Sancho-Araiz A; Mayawala K; Zalba S; Garrido MJ; de Alwis D; Troconiz IF; Freshwater T
    Clin Pharmacol Ther; 2023 Sep; 114(3):623-632. PubMed ID: 37170933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration.
    Parra-Guillen ZP; Freshwater T; Cao Y; Mayawala K; Zalba S; Garrido MJ; de Alwis D; Troconiz IF
    Front Pharmacol; 2021; 12():705443. PubMed ID: 34366859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab.
    Sancho-Araiz A; Parra-Guillen ZP; Troconiz IF; Freshwater T
    Clin Pharmacol Ther; 2024 Nov; 116(5):1304-1313. PubMed ID: 39037559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A generic viral dynamic model to systematically characterize the interaction between oncolytic virus kinetics and tumor growth.
    Titze MI; Frank J; Ehrhardt M; Smola S; Graf N; Lehr T
    Eur J Pharm Sci; 2017 Jan; 97():38-46. PubMed ID: 27825920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches.
    Eigenmann MJ; Karlsen TV; Krippendorff BF; Tenstad O; Fronton L; Otteneder MB; Wiig H
    J Physiol; 2017 Dec; 595(24):7311-7330. PubMed ID: 28960303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetic modeling of (18)F-SiFAlin-Asp3-PEG1-TATE in AR42J tumor bearing mice.
    Maaß C; Rivas JR; Attarwala AA; Hardiansyah D; Niedermoser S; Litau S; Wängler C; Wängler B; Glatting G
    Nucl Med Biol; 2016 Apr; 43(4):243-6. PubMed ID: 27067044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.
    Andtbacka RHI; Curti B; Daniels GA; Hallmeyer S; Whitman ED; Lutzky J; Spitler LE; Zhou K; Bommareddy PK; Grose M; Wang M; Wu C; Kaufman HL
    J Clin Oncol; 2021 Dec; 39(34):3829-3838. PubMed ID: 34464163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
    Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake.
    Laplanche R; Meno-Tetang GM; Kawai R
    J Pharmacokinet Pharmacodyn; 2007 Jun; 34(3):373-400. PubMed ID: 17431753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple Administration Routes, Including Intramuscular Injection, of Oncolytic Tanapoxvirus Variants Significantly Regress Human Melanoma Xenografts in BALB/c Nude Mice Reconstituted with Splenocytes from Normal BALB/c Donors.
    Monaco ML; Idris OA; Filpi GA; Kohler SL; Haller SD; Burr JE; Eversole R; Essani K
    Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune System, Friend or Foe of Oncolytic Virotherapy?
    Filley AC; Dey M
    Front Oncol; 2017; 7():106. PubMed ID: 28589085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic Viruses in Cancer Treatment: A Review.
    Lawler SE; Speranza MC; Cho CF; Chiocca EA
    JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of
    Siebinga H; de Wit-van der Veen BJ; Beijnen JH; Stokkel MPM; Dorlo TPC; Huitema ADR; Hendrikx JJMA
    EJNMMI Res; 2021 Aug; 11(1):73. PubMed ID: 34398356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic virus V937 in combination with PD-1 blockade therapy to target immunologically quiescent liver and colorectal cancer.
    Tran TQ; Grein J; Selman M; Annamalai L; Yearley JH; Blumenschein WM; Sadekova S; Chackerian AA; Phan U; Wong JC
    Mol Ther Oncol; 2024 Jun; 32(2):200807. PubMed ID: 38745749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice.
    Ganesh S; Gonzalez-Edick M; Gibbons D; Waugh J; Van Roey M; Jooss K
    Hum Gene Ther; 2009 Oct; 20(10):1201-13. PubMed ID: 19572803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically based pharmacokinetics of cyclosporine A: reevaluation of dose-nonlinear kinetics in rats.
    Tanaka C; Kawai R; Rowland M
    J Pharmacokinet Biopharm; 1999 Dec; 27(6):597-623. PubMed ID: 11153448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.